These characteristics of the Sputnik V vaccine make it very effective, know everything about the new vaccine

In India, the Russian-developed Corona Vaccine Sputnik V has been approved for emergency use. This is the third vaccine for the coronavirus to be approved after Kovshield (Serum Institute of India) and Kovaxin (Bharat Biotech).

The Sputnik V vaccine, developed by Moscow's Gamale National Research Institute of Epidemiology and Microbiology, uses two different viruses that cause the common cold (adenovirus) in humans. Adenovirus becomes weak so it cannot replicate in humans and cannot cause disease.

Let me tell you that this vaccine is also modified. For this reason, the vaccine provides a code for making the coronavirus spike protein. The purpose of this process is to ensure that when the actual virus tries to infect the body, it can mount an immune response in the form of antibodies.

Sputnik uses a different vector for each of the two shots during vaccination. According to this Russian Direct Investment Fund (RDIF), the same methods are used for both shots. It provides immunity with a longer duration than other vaccines. A difference of 21 days is required for both shots.

Sputnik V (liquid) is stored at a temperature of minus 18 ° C. However, its dried form can be stored at 2–8 ° C. This does not require investing in cold-chain infrastructure. According to the RDIF, Sputnik V has been approved for the use of more than 150 crore people in 55 countries. The vaccine is proposed to be priced below $ 10 per shot. Although its price in India has not been decided.

Dr. Reddy's labs based in Hyderabad sought government approval for the vaccine in India. RDIF partnered with Dr. Reddy's in September 2020 to conduct clinical trials in the country. On Monday, the Subject Expert Committee (SEC) of the Drugs Controller General of India took the Sputnik V application for Emergency Use Authority and moved on. DCGI previously sought additional data from the drug manufacturer.

Five other Indian companies have partnered with RDIF for Sputnik V. These include Gland Pharma, Hetero Biopharma, Virchow Biotech, Panacea Biotech, and Stellis Biopharma, Bangalore-based Strides Pharma Science's bioceramic. It is expected from their partnerships that India's capacity to manufacture this vaccine will exceed 60 million.